n-(butylsulfonyl)-o-[4-pyridin-4-yl]butyl]-l-tyrosine hydrochloride monohydrate - Names and Identifiers
Name | Tirofiban hydrochloride monohydrate
|
Synonyms | Tirofiban HCl Tirofiban HCl monohydrate Tirofiban hcl Monohydrate TIROFIBAN, HYDROCHLORIDE HYDRATE Tirofiban hydrochloride monohydrate n-butylsulfonyl-o-(4-(4-pyridinyl)butyl)-l-tyrosine hydrochloride monohydrate N-(Butylsulfonyl)-O-[4-(4-piperidynyl)butyl]-L-tyrosine, Hydrochloride Hydrate n-(butylsulfonyl)-o-[4-pyridin-4-yl]butyl]-l-tyrosine hydrochloride monohydrate n-(butylsulfonyl)-o-[4-(4-piperidynyl)butyl]-l-tyrosine hydrochloride monohydrate n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-l-tyrosine hydrochloride monohydrate N-(Butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine monohydrochloride monohydrate (2R)-3-(butylsulfonyl)-2-{4-[4-(piperidin-4-yl)butoxy]benzyl}propanoic acid hydrochloride hydrate (2S)-2-(Butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid hydrochloride hydrate (2s)-2-(butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid hydrochloride monohydrate
|
CAS | 150915-40-5
|
EINECS | 682-504-6 |
InChI | InChI=1/C23H37NO5S.ClH.H2O/c1-2-3-16-30(27,28)18-21(23(25)26)17-20-7-9-22(10-8-20)29-15-5-4-6-19-11-13-24-14-12-19;;/h7-10,19,21,24H,2-6,11-18H2,1H3,(H,25,26);1H;1H2/t21-;;/m0../s1 |
n-(butylsulfonyl)-o-[4-pyridin-4-yl]butyl]-l-tyrosine hydrochloride monohydrate - Physico-chemical Properties
Molecular Formula | C22H39ClN2O6S
|
Molar Mass | 495.07 |
Melting Point | 135-137°C |
Boling Point | 611.7℃ at 760 mmHg |
Solubility | DMSO: >12mg/mL at warmed to 60°C |
Appearance | White solid |
Color | white to beige |
Merck | 14,9464 |
Storage Condition | -20°C |
In vitro study | Tirofiban (MK-383, Aggrastat) is a non-peptide derivative of tyrosine that selectively inhibits the GP-IIb/IIIa receptor and has the lowest effect on the vβ3 Vitronectin receptor. Tirofiban inhibited gel-filtered platelet aggregation induced by 10 μm ADP with an IC50 of 9 nM, but inhibited human umbilical vein adhesion to Vitronectin with an IC50 of 62 μmol/L, this is dependent on the vβ3 receptor. |
In vivo study | Tirofiban(10 to 500 mg/kg or 10 micrograms/kg/min continuous intravenous infusion for 360 minutes) inhibits platelet aggregation with ADP and collagen in the canine model. Treatment of humans with Tirofiban at 0.15 μg/kg/min for 4 hours increased bleeding time 2.5-fold and inhibited 97% of ADP-induced platelet aggregation. |
n-(butylsulfonyl)-o-[4-pyridin-4-yl]butyl]-l-tyrosine hydrochloride monohydrate - Risk and Safety
Hazard Symbols | Xi - Irritant
|
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin.
|
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S37 - Wear suitable gloves.
S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
|
WGK Germany | 3 |
n-(butylsulfonyl)-o-[4-pyridin-4-yl]butyl]-l-tyrosine hydrochloride monohydrate - Introduction
Tirofiban hydrochloride monohydrate is an organic compound. The following is a description of its nature, use, preparation and safety information:
Nature:
-Appearance: Generally white crystalline powder.
-Solubility: Soluble in water and organic solvents such as ethanol and dimethyl sulfoxide.
-Stability: Relatively stable under regular experimental conditions.
Use:
- Tirofiban hydrochloride monohydrate is an important organic synthesis intermediate, which has a wide range of uses in drug synthesis and biochemical research.
-It can be used to synthesize anti-tumor drugs, antiviral drugs and biologically active compounds.
Preparation Method:
-The compound is generally prepared by organic synthesis methods, which require a series of chemical reagents and reaction steps for synthesis. The specific preparation method can be found through literature, patents or related materials.
Safety Information:
-The safety of Tirofiban hydrochloride monohydrate depends on its chemical properties, preparation conditions and uses.
-During use, follow laboratory safety practices and avoid contact with skin, eyes and inhalation.
-for specific safety information and risk assessment, it is recommended to refer to the relevant safety data sheet (SDS) and the safety instructions provided by the chemical supplier.
Last Update:2024-04-09 15:16:34